Details for New Drug Application (NDA): 215428
✉ Email this page to a colleague
NDA 215428 describes CITALOPRAM HYDROBROMIDE, which is a drug marketed by Almatica, Norvium Bioscience, Aurobindo Pharma, Chartwell Molecular, Hetero Labs Ltd Iii, Hikma, Pharm Assoc, Biovail Labs Intl, Amneal Pharms Ny, Apotex, Aurobindo, Chartwell Rx, Cosette, Dr Reddys Labs Ltd, Epic Pharma, Epic Pharma Llc, Fosun Pharma, Glenmark Pharms Ltd, Heritage Pharma, Invagen Pharms, Jubilant Generics, Mylan, Natco Pharma Ltd, Roxane, Sun Pharm Inds Inc, Sun Pharm Industries, Taro, and Torrent Pharms, and is included in thirty-four NDAs. It is available from forty-three suppliers. Additional details are available on the CITALOPRAM HYDROBROMIDE profile page.
The generic ingredient in CITALOPRAM HYDROBROMIDE is citalopram hydrobromide. There are fifty-six drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the citalopram hydrobromide profile page.
The generic ingredient in CITALOPRAM HYDROBROMIDE is citalopram hydrobromide. There are fifty-six drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the citalopram hydrobromide profile page.
Summary for 215428
| Tradename: | CITALOPRAM HYDROBROMIDE |
| Applicant: | Almatica |
| Ingredient: | citalopram hydrobromide |
| Patents: | 0 |
Pharmacology for NDA: 215428
| Mechanism of Action | Serotonin Uptake Inhibitors |
Medical Subject Heading (MeSH) Categories for 215428
Suppliers and Packaging for NDA: 215428
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CITALOPRAM HYDROBROMIDE | citalopram hydrobromide | CAPSULE;ORAL | 215428 | NDA | Almatica Pharma LLC | 52427-691 | 52427-691-30 | 30 CAPSULE in 1 BOTTLE (52427-691-30) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 30MG BASE | ||||
| Approval Date: | Jan 31, 2022 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
